Dr. Anderson has over 30 years of experience as a both a laboratory head and a Director of Clinical Pharmacology at Merck & Co. Inc., with expertise in all aspects of pharmaceutical drug discovery and development, from target identification through late clinical development and life cycle management. Areas of particular emphasis are infectious disease, oncology, CNS, and cardiovascular disease. He is a proven highly effective leader in relationship-sensitive business environments with a demonstrated ability to deliver results under pressure of timelines, budget constraints, and a complex regulatory environment.
Dr. Anderson has served on National Institute of Neurological Disorders and Stroke (NINDS) special emphasis grant review panels and NIH Scientific Review Roadmap Panels and has broad experience with regulatory agencies including IND, NDA, and FDA advisory meetings where he was clinical pharmacology responder for vorapaxar.
Dr. Anderson earned his Bachelor of Science Degree from Michigan State University (E. Lansing, MI, USA) with honors, and his PhD from University of Wisconsin-Madison (Madison, WI, USA) followed by postdoctoral work at the University of Utah. He has authored over 100 peer reviewed publications and abstracts in journals including Science, The Lancet, and The Journal of Clinical Endocrinology and Metabolism.
In his free time, Matt enjoys designing and building mid-power model rockets with his daughters.